| P50 | author | György Nagy | Q87876082 |
| P2093 | author name string | László Czirják | |
| | Zoltán Szekanecz | |
| | Márta Péntek | |
| | Petra Baji | |
| | Valentin Brodszky | |
| | László Gulácsi | |
| P2860 | cites work | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis | Q21134808 |
| | Tocilizumab for rheumatoid arthritis | Q24234126 |
| | Certolizumab pegol (CDP870) for rheumatoid arthritis in adults | Q24236701 |
| | Abatacept for rheumatoid arthritis | Q24240131 |
| | Golimumab for rheumatoid arthritis | Q24240895 |
| | Adalimumab for treating rheumatoid arthritis | Q24246674 |
| | Etanercept for the treatment of rheumatoid arthritis | Q24248004 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate | Q28295474 |
| | Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 |
| | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety | Q33328963 |
| | A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial | Q33675468 |
| | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group | Q33885648 |
| | Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial | Q33976382 |
| | Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab' | Q34125254 |
| | Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 |
| | Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 |
| | Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). | Q34544500 |
| | Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study | Q82777810 |
| | The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial | Q83008423 |
| | Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach | Q83016502 |
| | The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial | Q83223892 |
| | [Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model] | Q84141994 |
| | ??? | Q28295371 |
| | Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont | Q34547981 |
| | Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial | Q34552451 |
| | Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study | Q34601527 |
| | Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial | Q34609376 |
| | Scales to assess the quality of randomized controlled trials: a systematic review | Q34724144 |
| | Infliximab for the treatment of rheumatoid arthritis | Q34758388 |
| | IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial | Q34795777 |
| | Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis | Q35907809 |
| | Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study | Q36023494 |
| | Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 |
| | Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s | Q36550842 |
| | Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study | Q36610390 |
| | Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate | Q36930704 |
| | Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial | Q37172820 |
| | A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study | Q37206622 |
| | Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors | Q37404890 |
| | A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview | Q37428436 |
| | Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis | Q37829182 |
| | A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. | Q37919096 |
| | A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach | Q37940947 |
| | Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis | Q38112701 |
| | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis | Q38176549 |
| | Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial | Q38498967 |
| | The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 |
| | Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 |
| | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 |
| | Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study | Q45736528 |
| | Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. | Q45982095 |
| | Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study | Q46058399 |
| | Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. | Q48480707 |
| | Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 |
| | Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 |
| | Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b | Q60228496 |
| | Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig | Q79290408 |
| | Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group st | Q79765442 |
| | Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition | Q81216018 |
| | Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial | Q81658198 |
| | The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 |
| P921 | main subject | disease-modifying antirheumatic drug | Q810254 |
| | biosimilar | Q864715 |
| | rheumatoid arthritis | Q187255 |
| | globulins | Q321710 |
| | monoclonal antibody | Q422248 |
| | blood proteins | Q425056 |
| P304 | page(s) | S53-64 | |
| P577 | publication date | 2014-05-01 | |
| | 2014-05-16 | |
| P1433 | published in | The European Journal of Health Economics | Q24883230 |
| P1476 | title | Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison | |
| P478 | volume | 15 Suppl 1 | |